Research VEGF
Genentech Biooncology

Resources for this topic

multimedia callout footer

VEGF and angiogenesis in prostate cancer

“Higher levels of VEGF have been associated with adverse outcome in prostate cancer.”— Ryan, et al, Urol Oncol. 20061

A growing body of evidence suggests that the vascular endothelial growth factor (VEGF) ligand is an important mediator of angiogenesis in prostate cancer.1 Research has shown that:

  • Angiogenic factors such as the VEGF ligand are overexpressed in prostate cancer compared with nonmalignant prostate tissue1
  • VEGF has been implicated in pathologic angiogenesis associated with prostate cancer2,3
  • VEGF plays a key role in both localized and metastatic prostate cancer4-6
  • VEGF overexpression is associated with poor outcomes in prostate cancer7,8

Ongoing research continues to establish the involvement of VEGF in prostate cancer; however, further investigation is needed to shed more light on the multiple roles of VEGF.

In this section of ResearchVEGF.com, you can learn more about recent research on the role of VEGF and angiogenesis in prostate cancer, including evidence for and prevalence of VEGF expression in the disease, the role of VEGF throughout the development of prostate cancer, and the correlation of VEGF with prognosis.

For more information on VEGF and angiogenesis in prostate cancer, click on the links below.

In This Section

 
Next section

Evidence of VEGF expression

View references
for this site section